The world of infection prevention is buzzed with the potential of a novel oral therapy, TP-05, which promises a dramatic shift in Lyme disease prevention practices. This game-changer intends to focus on nipping Lyme disease in the bud by targeting the tick vector itself before transmission occurs. As the prevalence of Lyme disease escalates across…
The challenge of treating sepsis, an intricate and formidable critical health condition arising from an extreme reaction to infection, continues in healthcare facilities across the globe. Each year, millions fall victim to this life-threatening form of organ dysfunction, calling for more effective healthcare solutions. New insights gleaned from the ImmunoSep trial suggest that an advanced…
In a recent development, the National Institutes of Health (NIH) has announced a newly revised categorization for basic experimental studies involving humans (BESH). As per the agency's announcement on January 29, BESH applications will not be subjected to clinical trial requirements effective from May 25, 2026. However, there remains an expectation for such studies to…
Delving into the real-world efficacy and safety of fecal microbiota or Rebyota outlined by Paul Feuerstadt, MD, paints a considerably reassuring picture of this therapeutic agent in dealing with recurrent C difficile. Rebyota has enjoyed FDA approval for over two years, and Dr. Feuerstadt, associate clinical professor of Medicine at Yale School of Medicine, who…
Surgical site infections (SSIs) remain widespread in spite of development in surgical techniques and preventive measures. As such, treatment methods continue to be evaluated to find promising solutions. One such method involves the use of topical antibiotics such as gentamicin. This article delves into a recent randomized controlled trial aiming to assess the effectiveness of…
Ondine Biomedical, a Canadian company specializing in life sciences, has declared that it is stepping up the final preparations to kick off its key US Phase 3 clinical trial in Q4 2024. This acceleration comes in the wake of a successful fundraiser that totalled Cdn $16 million (US $11m), attracting substantial support from existing institutional…
The IMPACT Collaboratory recently hosted Dr. Susan Huang, a renowned medical professional and impactful authority in the realm of healthcare-associated infections and multidrug-resistant organisms (MDROs), for one of the grand rounds. Dr. Huang's position as a professor at the University of California Irvine School of Medicine, in the Division of Infectious Diseases and the Health…
A hospital on Long Island is one of three sites nationally spearheading clinical trials for an experimental nasal COVID-19 vaccine. This vaccine could potentially diminish disease transmission and infection rates, offering fresh hope in the ongoing pandemic. The trials are taking place at NYU Langone Hospital-Long Island in Mineola, which is actively recruiting eligible adults…
A recent study published in The Lancet Infectious Diseases announced transformative results from a randomized clinical trial focusing on patients with low-risk Staphylococcus aureus bloodstream infections. The trial conducted across 31 hospitals in Germany, France, the Netherlands, and Spain, showed that an early switch from intravenous (IV) to oral antibiotic therapy was as effective as…